Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer

Oncotarget

Volumn 7, Issue 38, 2016, Pages 61336-61354

  Auer, Katharina ^a   Bachmayr Heyda, Anna ^a   Sukhbaatar, Nyamdelger ^a   Aust, Stefanie ^a   Schmetterer, Klaus G ^b   Meier, Samuel M ^c   Gerner, Christopher ^c   Grimm, Christoph ^a   Horvat, Reinhard ^b   Pils, Dietmar ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Epithelial ovarian cancer; Flow cytometry; Next generation sequencing; PD 1; Peritoneal tumor spread

Indexed keywords

C REACTIVE PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; ASCITES; B LYMPHOCYTE; BLOOD; CANCER GRADING; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; METABOLOMICS; MONOCYTE; NATURAL KILLER T CELL; OVARY CANCER; PERITONEUM METASTASIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RNA SEQUENCE; TUMOR CELL; TUMOR MICROENVIRONMENT; CELL SEPARATION; CYTOLOGY; DISEASE EXACERBATION; IMMUNOLOGY; METABOLISM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; SECONDARY; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ADAPTIVE IMMUNITY; ANTIGENS, NEOPLASM; ASCITES; B-LYMPHOCYTES; CELL SEPARATION; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, INNATE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; METABOLOMICS; MONOCYTES; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SEQUENCE ANALYSIS, RNA; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84992525150     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11038     Document Type: Article

References (49)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013; 3:256.
3. Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piche A. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015; 15:492.
4. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, et al. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102:18538-18543.
5. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol. 2001; 31:3121-3127.
6. Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013; 25:214-221.
7. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:5198-5208.
8. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-615.
9. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013; 123:517-525.
10. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 2014; 106.
11. Auer K, Bachmayr-Heyda A, Aust S, Sukhbaatar N, Reiner AT, Grimm C, Horvat R, Zeillinger R, Pils D. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget. 2015; 6:17261-17275; doi: 17210.18632/oncotarget.13746.
12. Bachmayr-Heyda A, Auer K, Sukhbaatar N, Aust S, Deycmar S, Reiner AT, Polterauer S, Dekan S, Pils D. Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread. Oncotarget. 2016; doi: 10.18632/oncotarget.9243.
13. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009; 126:458-465.
14. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL, Cook GP. Human tumour immune evasion via TGF-beta blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One. 2011; 6:e22842.
15. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004; 4:371-379.
16. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin activates human B cells to secrete TNF-alpha, IL-6, and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. J Clin Immunol. 2011; 31:472-478.
17. Wu J, Cunha FQ, Liew FY, Weiser WY. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J Immunol. 1993; 151:4325-4332.
18. Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lungconditioned medium. J Biol Chem. 1977; 252:1998-2003.
19. Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, Zhang Y, Zhang L, Yuan ZR, Tan HS, Das G, Devadas S. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006; 16:126-133.
20. Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. Eur Cytokine Netw. 2013; 24:106-113.
21. Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst. 2014; 106:dju200.
22. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998; 394:485-490.
23. East J, Travis C, Webb T. Increase in natural killer T (NKT) Cell activation in hypoxic environments via the induction of HIF1alpha. The Journal of Immunology. 2012; 188(Meeting Abstracts 1):162.116.
24. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, Rubio R, April C, Chen J, Wickham-Garcia E, Liu J, Culhane A, Drapkin R, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012; 7:e30269.
25. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192:1027-1034.
26. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015; 112:1501-1509.
27. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014; 110:1409-1412.
28. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Advances in cancer research. 1997; 71:241-319.
29. Lu Y, Huang S, Li P, Chen B, Liu W, Chen Z, Yin F. Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer. Exp Ther Med. 2015; 9:2003-2007.
30. Ranjan P, Sodhi A, Srivastava A. Cisplatin and interferongamma treated murine macrophages induce apoptosis in tumor cell lines. Anticancer Drugs. 1997; 8:797-806.
31. Muenchen HJ, Aggarwal SK. Activation of murine peritoneal macrophages after cisplatin and taxol combination. Anticancer Drugs. 1997; 8:784-789.
32. Manthey CL, Perera PY, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol. 1994; 152:825-831.
33. Nakamura H, Makino Y, Okamoto K, Poellinger L, Ohnuma K, Morimoto C, Tanaka H. TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J Immunol. 2005; 174:7592-7599.
34. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol. 2004; 173:6418-6426.
35. Nunez-Cruz S, Quinn III W, Connolly D, Scholler N. B cells infiltrating ovarian cancer exhibit a regulatory-like phenotype. The Journal of Immunology. 2011; 186(Meeting Abstracts 1):66.26.
36. Zhang Y, Morgan R, Podack ER, Rosenblatt J. B cell regulation of anti-tumor immune response. Immunol Res. 2013; 57:115-124.
37. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006; 66:7741-7747.
38. Shah S, Divekar AA, Hilchey SP, Cho HM, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH, Rosenblatt JD. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005; 117:574-586.
39. Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W, Lu X. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol. 2015.
40. Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, Budczies J, Bockmayr M, Dietel M, Denkert C, Braicu I, Johrens K. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget. 2016; 7:1486-1499; doi: 1410.18632/oncotarget.16429.
41. Hayes CS, Burns MR, Gilmour SK. Polyamine blockade promotes antitumor immunity. Oncoimmunology. 2014; 3:e27360.
42. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey KJ. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med. 1997; 185:1759-1768.
43. Yellapa A, Bitterman P, Sharma S, Guirguis AS, Bahr JM, Basu S, Abramowicz JS, Barua A. Interleukin 16 expression changes in association with ovarian malignant transformation. Am J Obstet Gynecol. 2014; 210:272 e271-210.
44. Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H. Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression. Cancer Res. 2015; 75:1777-1781.
45. Malaterre J, Strambi C, Aouane A, Strambi A, Rougon G, Cayre M. A novel role for polyamines in adult neurogenesis in rodent brain. Eur J Neurosci. 2004; 20:317-330.
46. Schwab JM, Schluesener HJ, Seid K, Meyermann R. IL-16 is differentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. Int J Dev Neurosci. 2001; 19:93-100.
47. Tenenbaum JB, de Silva V, Langford JC. A global geometric framework for nonlinear dimensionality reduction. Science. 2000; 290:2319-2323.
48. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47.
49. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, Kim CJ, Kusanovic JP, Romero R. A novel signaling pathway impact analysis. Bioinformatics. 2009; 25:75-82.